Videos

Mark Kris, MD: Evaluating Therapeutic Options

April 26th 2016

Mark Kris, MD: Choosing a Treatment in NSCLC

April 26th 2016

Mark Kris, MD: Lacking Actionable Mutations in NSCLC

April 26th 2016

mCRC with Tanios Bekaii-Saab, MD and Tara Seery, MD: Case 2

April 26th 2016

mCRC with Tanios Bekaii-Saab, MD and Tara Seery, MD

Tanios Bekaii-Saab, MD; Chemotherapy as a Possible Option

April 26th 2016

Tara Seery, MD; Chemotherapy as a Possible Option

April 26th 2016

Tanios Bekaii-Saab, MD: KRAS Status in mCRC

April 26th 2016

Tara Seery, MD: KRAS Status in mCRC

April 26th 2016

Tanios Bekaii-Saab, MD: Impact of Third-Line Therapy

April 26th 2016

Tara Seery, MD: Impact of Third-Line Therapy

April 26th 2016

Tanios Bekaii-Saab, MD: Clinical Data Supporting Trifluradine-Tipiracil

April 26th 2016

Tara Seery, MD: Clinical Data Supporting Trifluradine-Tipiracil

April 26th 2016

Tanios Bekaii-Saab, MD: Fourth-Line Therapy in mCRC

April 26th 2016

Tara Seery, MD: Fourth-Line Therapy in mCRC

April 26th 2016

Charles Fuchs, MD: Cost Issues With CT Regimens and Bevacizumab

April 26th 2016

Charles Fuchs, MD: Strategies to Increase RAS Testing

April 26th 2016

Charles Fuchs, MD: Impeding RAS Mutation Testing

April 26th 2016

Charles Fuchs, MD: Percentage of RAS Mutation Tests in Metastatic CRC

April 26th 2016

Charles Fuchs, MD: RAS Mutations and the Sequence of Therapies

April 26th 2016

Charles Fuchs, MD: Clinical Importance of RAS Mutations

April 26th 2016

Charles Fuchs, MD: RAS Mutations in Metastatic Colorectal Cancer

April 26th 2016

Tanios Bekaii-Saab, MD: Cost Issues With CT Regimens and Bevacizumab

April 26th 2016

Tanios Bekaii-Saab, MD: Strategies to Increase RAS Testing

April 26th 2016

Tanios Bekaii-Saab, MD: Impeding RAS Mutation Testing

April 26th 2016

Tanios Bekaii-Saab, MD: Percentage of RAS Mutation Tests in Metastatic CRC

April 26th 2016

Tanios Bekaii-Saab, MD: RAS Mutations and the Sequence of Therapies

April 26th 2016

Tanios Bekaii-Saab, MD: Clinical Importance of RAS Mutations

April 26th 2016

Tanios Bekaii-Saab, MD: RAS Mutations in Metastatic Colorectal Cancer

April 26th 2016

Tanios Bekaii-Saab, MD: Mutations in Colorectal Cancer

April 26th 2016

Unresectable Colon Cancer with Charles Fuchs, MD and Tanios Bekaii-Saab, MD: Case 2

April 26th 2016

Unresectable Colon Cancer with Charles Fuchs, MD and Tanios Bekaii-Saab, MD

Videos

Mark Kris, MD: Evaluating Therapeutic Options

Mark Kris, MD: Choosing a Treatment in NSCLC

Mark Kris, MD: Lacking Actionable Mutations in NSCLC

mCRC with Tanios Bekaii-Saab, MD and Tara Seery, MD: Case 2

Tanios Bekaii-Saab, MD; Chemotherapy as a Possible Option

Tara Seery, MD; Chemotherapy as a Possible Option

Tanios Bekaii-Saab, MD: KRAS Status in mCRC

Tara Seery, MD: KRAS Status in mCRC

Tanios Bekaii-Saab, MD: Impact of Third-Line Therapy

Tara Seery, MD: Impact of Third-Line Therapy

Tanios Bekaii-Saab, MD: Clinical Data Supporting Trifluradine-Tipiracil

Tara Seery, MD: Clinical Data Supporting Trifluradine-Tipiracil

Tanios Bekaii-Saab, MD: Fourth-Line Therapy in mCRC

Tara Seery, MD: Fourth-Line Therapy in mCRC

Charles Fuchs, MD: Cost Issues With CT Regimens and Bevacizumab

Charles Fuchs, MD: Strategies to Increase RAS Testing

Charles Fuchs, MD: Impeding RAS Mutation Testing

Charles Fuchs, MD: Percentage of RAS Mutation Tests in Metastatic CRC

Charles Fuchs, MD: RAS Mutations and the Sequence of Therapies

Charles Fuchs, MD: Clinical Importance of RAS Mutations

Charles Fuchs, MD: RAS Mutations in Metastatic Colorectal Cancer

Tanios Bekaii-Saab, MD: Cost Issues With CT Regimens and Bevacizumab

Tanios Bekaii-Saab, MD: Strategies to Increase RAS Testing

Tanios Bekaii-Saab, MD: Impeding RAS Mutation Testing

Tanios Bekaii-Saab, MD: Percentage of RAS Mutation Tests in Metastatic CRC

Tanios Bekaii-Saab, MD: RAS Mutations and the Sequence of Therapies

Tanios Bekaii-Saab, MD: Clinical Importance of RAS Mutations

Tanios Bekaii-Saab, MD: RAS Mutations in Metastatic Colorectal Cancer

Tanios Bekaii-Saab, MD: Mutations in Colorectal Cancer

Unresectable Colon Cancer with Charles Fuchs, MD and Tanios Bekaii-Saab, MD: Case 2

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

ASCO 2026 Highlights: Breast & Lung Cancer Advances With Ajaz Khan, MD

Sunvozertinib Outperforms Chemotherapy as First-Line Therapy for EGFR Exon 20–Mutant NSCLC

FDA Grants Priority Review to Adjuvant Atezolizumab for dMMR Colon Cancer

FDA Grants Rare Pediatric Disease Designation to Opaganib for Neuroblastoma

Generic Larotrectinib Capsules Gain Tentative FDA Approval